Participants
Median age was 75 years (55 to 88 years); Baseline median PSA was 52.3 ng/ml (0.03 to 6884); Median haemoglobin was 12.4 g/dL (7.6 to 16.0). Median alkaline phosphatase was 109 (38 to 2728). Bone metastasis, Nodal metastasis and Visceral metastasis were present in 90%, 38%, and 14%, respectively. Ninety-four patients (63%) were Docetaxel naive.
Main outcome measures
The prognostic and predictive value of baseline neutrophil-lymphocyte ratio was assessed.
Results
Baseline median NLR was 3.05 (range 0.8 to 32.4) and mean NLR 4.58 (95% CI 3.82 to 5.33). The overall PSA 50% response rate was 49%. Haemoglobin >11.0 was associated with better PSA response with an odds ratio of 2.4 (95% CI 1.2 to 4.8). Chemotherapy naive patients, as expected, also had a better response to Abiraterone with an odds ratio of 3.1 (95% CI 1.4 to 7.3).
A high NLR >4 was confirmed to be prognostic and was associated with inferior overall survival (1-year survival rate 59% vs 77%, log rank test: p ¼ 0.054). But contrary to van Soest et al. 1 findings, NLR, as a dichotomised variable, was not predictive of treatment response at any ratio (NLR 2, 3, 4 or 5). For instance, with a NLR ratio of 4, the PSA 50% response rate was 55% versus 47% in high (<4) and low (<4) NLR groups, respectively (chi-square test p-value 0.32). Furthermore, NLR, as continuous variable, was also not predictive of treatment response (odds ratio 1.05 on logistic regression p 0.172).
There was no imbalance in patient characteristics such as age, baseline PSA, haemoglobin, ALP, sites of metastasis (bone, vertebral or nodes) between high (<4) and low (>4) NLR groups (p-value at least >0.1 on Mann-Whitney, chi-square or student t-test as appropriate).
More patients pre-treated with Docetaxel had a high NLR of >4 (48% vs 31.3% vs p ¼ 0.046). But on subgroup analysis, NLR was not predictive of treatment response both in Docetaxel naive and Docetaxel exposed patients (Chi-square p 0.30 and p 0.784, respectively).
The discordant results could be explained by the fact that high NLR is a global and not a cancer specific biomarker. 6 High NLR has been associated with adverse outcomes in many common surgical and medical conditions. For instance, a high NLR is associated with increased cardiovascular disease mortality, smoking, diabetes, hypertension, hypercholesterolemia, ageing, body mass index, renal failure, metabolic syndrome, chronic obstructive pulmonary disease, and heart failure. 6 
Conclusion
We conclude that in this non-trial population, where there is a higher prevalence of comorbid medical conditions, NLR, although prognostic, is not a useful predictive biomarker for optimising the sequencing of hormonal and chemotherapeutic agents in metastatic castration-resistant prostate cancer. Contributorship: SS: idea for the study, analysed data, wrote and approved the final draft. MO: collected data, analysed data and approved the final draft.
